Who owns Lakefront Biotherapeutics NV?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of LKFT from SEC Form 13F filings across 76 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 76 institutions disclosed 32.1M shares of Lakefront Biotherapeutics NV worth $960.3M — about 43.5% of shares outstanding; the largest disclosed holder is GILEAD SCIENCES, INC.. Source: SEC Form 13F filings, parsed by EvidInvest.
76
13F holders
$960.3M
value, 2026 filers
43.5%
of shares outstanding (32.1M sh)
9
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of LKFT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 16.7M | $500.2M | 30.3% | 22.7% | 0.0% |
| 2 | TANG CAPITAL MANAGEMENT LLC | 3.8M | $113.5M | 5.2% | 5.1% | 0.0% |
| 3 | Madison Avenue Partners, LP | 3.4M | $103.4M | 4.4% | 4.7% | +39.9% |
| 4 | Prosight Management, LP | 2.0M | $61.3M | 10.6% | 2.8% | +31.8% |
| 5 | EcoR1 Capital, LLC | 1.7M | $50.0M | 2.4% | 2.3% | 0.0% |
| 6 | AMERIPRISE FINANCIAL INC | 1.3M | $38.1M | 0.0% | 1.7% | -10.7% |
| 7 | DME Capital Management, LP | 482,746 | $14.5M | 0.4% | 0.7% | 0.0% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 407,800 | $12.2M | 0.0% | 0.6% | +29.3% |
| 9 | BlackRock, Inc. | 338,152 | $10.1M | 0.0% | 0.5% | +8.3% |
| 10 | Point72 Asset Management, L.P. | 269,814 | $8.1M | 0.0% | 0.4% | -18.8% |
| 11 | D. E. Shaw & Co., Inc. | 197,844 | $5.9M | 0.0% | 0.3% | -8.3% |
| 12 | MILLENNIUM MANAGEMENT LLC | 181,090 | $5.4M | 0.0% | 0.2% | +67.8% |
| 13 | UBS Group AG | 168,148 | $5.0M | 0.0% | 0.2% | -4.1% |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 151,886 | $4.6M | 0.0% | 0.2% | +1034.6% |
| 15 | DAFNA Capital Management LLC | 130,175 | $3.9M | 0.7% | 0.2% | 0.0% |
| 16 | CITADEL ADVISORS LLC | 88,343 | $2.6M | 0.0% | 0.1% | -29.0% |
| 17 | TWO SIGMA INVESTMENTS, LP | 81,749 | $2.5M | 0.0% | 0.1% | +216.1% |
| 18 | NORGES BANKNEW | 76,879 | $2.3M | 0.0% | 0.1% | new |
| 19 | ALPS ADVISORS INC | 65,523 | $2.0M | 0.0% | 0.1% | +22.1% |
| 20 | GOLDMAN SACHS GROUP INC | 56,581 | $1.7M | 0.0% | 0.1% | +24.7% |
| 21 | AMERICAN CENTURY COMPANIES INC | 40,804 | $1.2M | 0.0% | 0.1% | +5.2% |
| 22 | BAROMETER CAPITAL MANAGEMENT INC. | 40,800 | $1.2M | 0.3% | 0.1% | +7.1% |
| 23 | MORGAN STANLEY | 37,682 | $1.1M | 0.0% | 0.1% | +41.6% |
| 24 | Schonfeld Strategic Advisors LLCNEW | 32,597 | $977,256 | 0.0% | 0% | new |
| 25 | MARSHALL WACE, LLPNEW | 32,399 | $971,321 | 0.0% | 0% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.